PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
176 hedge funds and large institutions have $397M invested in PDL BioPharma, Inc. in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 27 closing their positions.
5% more call options, than puts
Call options by funds: $214K | Put options by funds: $204K
3% more capital invested
Capital invested by funds: $387M → $397M (+$9.89M)
6% less funds holding
Funds holding: 187 → 176 (-11)
28% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 65
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.37M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$4.31M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$3.12M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.08M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.39M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$3.76M |
| 3 |
Millennium Management
New York
|
-$3.61M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.78M |
| 5 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$2.77M |
PDLI Hedge Fund Activity: Q1 2018 in Review
176 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2018, worth a combined $397M — up 2.6% from $387M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PDLI and 18 opened new positions — a net loss of 9 holders — while 65 trimmed existing stakes and 47 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $4.37M. The largest seller was Morgan Stanley, cutting an estimated $6.39M.
- 176 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2018, down from 187 in Q4 2017.
- Funds reported $397M of PDL BioPharma, Inc. stock for Q1 2018, up 2.6% quarter-over-quarter.
- 18 funds opened new PDL BioPharma, Inc. positions in Q1 2018 and 27 closed out, a net change of -9 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $4.37M added.
- The largest PDL BioPharma, Inc. seller in Q1 2018 was Morgan Stanley, an estimated $6.39M sold.
Based on aggregated 13F filings for Q1 2018.